Advances in the pharmacological management of bronchopulmonary dysplasia: an update of the literature

References

• Programme NNA. National neonatal audit programme (NNAP) summary report on 2022 data. [ Online]. Royal College of Paediatrics and Child Health; [cited 2024 Apr 30]. Available from: https://www.rcpch.ac.uk/sites/default/files/2023-12/nnap_summary_report_on_2022_data_version_2.pdf2023
   Google Scholar
• Profgram NNA. National neonatal audit programme (NNAP) summary report on 2021 data (online). Royal College of Paediatrics and Child Health. Available from: https://www.rcpch.ac.uk/sites/default/files/2022-10/nnap_summary_report_on_2021_data.pdf2022
   Google Scholar
• Programme NNA. National neonatal audit programme annual report on 2020 data. [ Online]. Royal College of Paediatrics and Child Health. Available from: https://www.rcpch.ac.uk/sites/default/files/20222020
   Google Scholar
• Programme NNA. National neonatal audit programme 2020 annual report on 2019 data. [ Online]. Royal College of Paediatrics and Child Health. Available from: https://www.rcpch.ac.uk/sites/default/files/2021-04/nnap_report_2020-v2.pdf2020
   Google Scholar
• BFBBPo S. Prematurity statistics in the UK. [ Online]. Bliss. 2022.
   Google Scholar
• Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001 Jun;163(7):1723–1729. doi: 10.1164/ajrccm.163.7.2011060
   PubMedGoogle Scholar
• Northway WH Jr., Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease Bronchopulmonary Dysplasia. N Engl J Med. 1967 Feb 16;276(7):357–368. doi: 10.1056/NEJM196702162760701
   PubMed Web of Science ®Google Scholar
• Davidson LM, Berkelhamer SK. Bronchopulmonary dysplasia: chronic lung disease of infancy and long-term pulmonary outcomes. J Clin Med. 2017 Jan 6;6(1):4. doi: 10.3390/jcm6010004
   PubMed Web of Science ®Google Scholar
• Yao S, Uthaya S, Gale C, et al. Postnatal corticosteroid use for prevention or treatment of bronchopulmonary dysplasia in England and Wales 2012-2019: a retrospective population cohort study. BMJ Open. 2022 Nov 17;12(11):e063835. doi: 10.1136/bmjopen-2022-063835
   PubMed Web of Science ®Google Scholar
• Jenkinson AC, Kaltsogianni O, Dassios T, et al. Postnatal corticosteroid usage in United Kingdom and Ireland neonatal units. Acta Paediatr. 2023 Dec;112(12):2503–2506. doi: 10.1111/apa.16968
   PubMed Web of Science ®Google Scholar
• Excellence NIfHa C. Specialist neonatal respiratory care for babies born preterm. [ Online]. National Institute for Health and Care Excellence. Available from: https://www.nice.org.uk/guidance/ng124/chapter/Recommendations#respiratory-support-for-preterm-babies2019
   Google Scholar
• Harris C, Bisquera A, Zivanovic S, et al. Postnatal dexamethasone exposure and lung function in adolescents born very prematurely. PLOS ONE. 2020;15(8):e0237080. doi: 10.1371/journal.pone.0237080
   PubMed Web of Science ®Google Scholar
• Doyle LW, Cheong JL, Hay S, et al. Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2021 Nov 11;2021(11):CD001145. doi: 10.1002/14651858.CD001145.pub5
   Google Scholar
• Onland W, Offringa M, van Kaam A. Late (>/= 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017 Aug 24;8(8):CD002311. doi: 10.1002/14651858.CD002311.pub4
   PubMedGoogle Scholar
• Shah SS, Ohlsson A, Halliday HL, et al. Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev. 2017 Oct 16;10(10):CD002057. doi: 10.1002/14651858.CD002057.pub4
   PubMedGoogle Scholar
• Al-Taweel HM, Abdelhady ISI, Irfan N, et al. Comparing low-dose (DART) and enhanced low-dose dexamethasone regimens in preterm infants with bronchopulmonary dysplasia. Front Pediatr. 2023;11:1261316. doi: 10.3389/fped.2023.1261316
   PubMed Web of Science ®Google Scholar
• Baek SH, Shin JE, Han J, et al. Factors associated with the response to postnatal dexamethasone use in very low birthweight infants: a nationwide cohort study. BMJ Paediatr Open. 2023 Dec 18;7(1):e002302. doi: 10.1136/bmjpo-2023-002302
   PubMedGoogle Scholar
• Clauss C, Thomas S, Khodak I, et al. Hydrocortisone and bronchopulmonary dysplasia: variables associated with response in premature infants. J Perinatol. 2020 Sep;40(9):1349–1357. doi: 10.1038/s41372-020-0680-7
   PubMed Web of Science ®Google Scholar
• Cuna A, Quiqley A, Varghese K, et al. Effectiveness and safety of repeat dexamethasone for bronchopulmonary dysplasia. J Perinatol. 2021 Aug;41(8):1956–1962. doi: 10.1038/s41372-021-01125-3
   PubMed Web of Science ®Google Scholar
• Onland W, Cools F, Kroon A, et al. Effect of hydrocortisone therapy initiated 7 to 14 days after birth on mortality or bronchopulmonary dysplasia among very preterm infants receiving mechanical ventilation: a randomized clinical trial. JAMA. 2019 Jan 29;321(4):354–363. doi: 10.1001/jama.2018.21443
   PubMed Web of Science ®Google Scholar
• Ben Said M, Hays S, Loys CM, et al. Postnatal steroids in extremely low birth weight infants: betamethasone or hydrocortisone? Acta Paediatr. 2013 Jul;102(7):689–694. doi: 10.1111/apa.12255
   PubMed Web of Science ®Google Scholar
• Buyuktiryaki M, Alyamac Dizdar E, Okur N, et al. Postnatal hydrocortisone therapy for the treatment of bronchopulmonary dysplasia in very low birth weight infants. Ann Med Res. 2021;26(12):2990–2996. doi: 10.5455/annalsmedres.2019.09.545
   Google Scholar
• Ob E, Byrne AO, Dowling J, et al. Diuretics use in the management of bronchopulmonary dysplasia in preterm infants: a systematic review. Acta Paediatr. 2024 Mar;113(3):394–402. doi: 10.1111/apa.17093
   PubMed Web of Science ®Google Scholar
• Tan C, Sehgal K, Sehgal K, et al. Diuretic use in infants with developing or established chronic lung disease: a practice looking for evidence. J Paediatr Child Health. 2020 Aug;56(8):1189–1193. doi: 10.1111/jpc.14877
   PubMed Web of Science ®Google Scholar
• Kasniya G, Weinberger B, Cerise J, et al. Lung ultrasound assessment of pulmonary edema in neonates with chronic lung disease before and after diuretic therapy. Pediatr Pulmonol. 2022 Dec;57(12):3145–3150. doi: 10.1002/ppul.26150
   PubMed Web of Science ®Google Scholar
• Slaughter JL, Klebanoff MA, Hade EM. Estimating the effect of diuretics and inhaled corticosteroids for evolving bronchopulmonary dysplasia in preterm infants. Paediatr Perinat Epidemiol. 2024 Jan 8. doi: 10.1111/ppe.13038
   PubMed Web of Science ®Google Scholar
• Zhu F, Ibarra Rios D, Joye S, et al. Cardiopulmonary physiological effects of diuretic therapy in preterm infants with chronic pulmonary hypertension. J Perinatology. 2023 Oct 01;43(10):1288–1294. doi: 10.1038/s41372-023-01742-0
   PubMed Web of Science ®Google Scholar
• Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006 May 18;354(20):2112–2121. doi: 10.1056/NEJMoa054065
   PubMed Web of Science ®Google Scholar
• Sanchez-Solis M, Garcia-Marcos PW, Aguera-Arenas J, et al. Impact of early caffeine therapy in preterm newborns on infant lung function. Pediatr Pulmonol. 2020 Jan;55(1):102–107. doi: 10.1002/ppul.24540
   PubMed Web of Science ®Google Scholar
• O’Reilly M, Sozo F, Harding R. Impact of preterm birth and bronchopulmonary dysplasia on the developing lung: long-term consequences for respiratory health. Clin Exp Pharmacol Physiol. 2013;40(11):765–773. doi: 10.1111/1440-1681.12068
   PubMed Web of Science ®Google Scholar
• Jukema M, Borys F, Sibrecht G, et al. Antileukotrienes for the prevention and treatment of chronic lung disease in very preterm newborns: a systematic review. Respir Res. 2021 Jul 17;22(1):208. doi: 10.1186/s12931-021-01800-1
   PubMed Web of Science ®Google Scholar
• Ng G, Bruschettini M, Ibrahim J, et al. Inhaled bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2024 Apr 9;4(4):CD003214. doi: 10.1002/14651858.CD003214.pub4
   PubMedGoogle Scholar
• Euteneuer JC, Kerns E, Leiting C, et al. Inhaled bronchodilator exposure in the management of bronchopulmonary dysplasia in hospitalized infants. J Perinatol. 2021 Jan;41(1):53–61. doi: 10.1038/s41372-020-0760-8
   PubMed Web of Science ®Google Scholar
• Napolitano N, Dysart K, Soorikian L, et al. Tolerability and efficacy of two doses of aerosolized albuterol in ventilated infants with BPD: a randomized controlled crossover trial. Pediatr Pulmonol. 2021 Jan;56(1):97–104. doi: 10.1002/ppul.25131
   PubMed Web of Science ®Google Scholar
• Sun Z, Lu H, Yang B, et al. Montelukast sodium to prevent and treat bronchopulmonary dysplasia in very preterm infants: a quasi-randomized controlled trial. J Clin Med. 2023 Dec 18;12(24):7745. doi: 10.3390/jcm12247745
   PubMed Web of Science ®Google Scholar
• Rupprecht T, Rupprecht C, Harms D, et al. Leukotriene receptor blockade as a life-saving treatment in severe bronchopulmonary dysplasia. Respiration. 2014;88(4):285–290. doi: 10.1159/000365488
   PubMed Web of Science ®Google Scholar
• Kim SB, Lee JH, Lee J, et al. The efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia. Korean J Pediatr. 2015 Sep;58(9):347–353. doi: 10.3345/kjp.2015.58.9.347
   PubMedGoogle Scholar
• Trachsel D, Erb TO, Hammer J, et al. Developmental respiratory physiology. Paediatr Anaesth. 2022 Feb;32(2):108–117. doi: 10.1111/pan.14362
   PubMed Web of Science ®Google Scholar
• Jensen EA, White AM, Liu P, et al. Determinants of severe metabolic bone disease in very low-birth-weight infants with severe bronchopulmonary dysplasia admitted to a tertiary referral center. Am J Perinatol. 2016 Jan 04;2(01):107–113. doi: 10.1055/s-0035-1560043
   Google Scholar
• Vazquez-Gomis R, Bosch-Gimenez V, Juste-Ruiz M, et al. Zinc concentration in preterm newborns at term age, a prospective observational study. BMJ Paediatr Open. 2019;3(1):e000527. doi: 10.1136/bmjpo-2019-000527
   PubMedGoogle Scholar
• Staub E, Evers K, Askie LM. Enteral zinc supplementation for prevention of morbidity and mortality in preterm neonates. Cochrane Database Syst Rev. 2021 Mar 12;3(3):CD012797. doi: 10.1002/14651858.CD012797.pub2
   PubMedGoogle Scholar
• De Luca LM. Multiple mechanisms: the example of vitamin A. Basic Life Sci. 1993;61:17–25.
   PubMedGoogle Scholar
• Massaro D, Massaro GD. Lung development, lung function, and retinoids. N Engl J Med. 2010 May 13;362(19):1829–1831. doi: 10.1056/NEJMe1002366
   PubMed Web of Science ®Google Scholar
• Ozer EA, Kumral A, Ozer E, et al. Effect of retinoic acid on oxygen-induced lung injury in the newborn rat. Pediatr Pulmonol. 2005 Jan;39(1):35–40. doi: 10.1002/ppul.20131
   PubMed Web of Science ®Google Scholar
• James ML, Ross AC, Bulger A, et al. Vitamin a and retinoic acid act synergistically to increase lung retinyl esters during normoxia and reduce hyperoxic lung injury in newborn mice. Pediatr Res. 2010 Jun;67(6):591–597. doi: 10.1203/PDR.0b013e3181dbac3d
   PubMed Web of Science ®Google Scholar
• Ng-Blichfeldt JP, Alcada J, Montero MA, et al. Deficient retinoid-driven angiogenesis may contribute to failure of adult human lung regeneration in emphysema. Thorax. 2017 Jun;72(6):510–521. doi: 10.1136/thoraxjnl-2016-208846
   PubMed Web of Science ®Google Scholar
• Rakshasbhuvankar AA, Simmer K, Patole SK, et al. Enteral vitamin a for reducing severity of bronchopulmonary dysplasia: a randomized trial. Pediatrics. 2021 Jan;147(1). doi: 10.1542/peds.2020-009985
   PubMed Web of Science ®Google Scholar
• El-Khuffash A, Mullaly R, McNamara PJ. Patent ductus arteriosus, bronchopulmonary dysplasia and pulmonary hypertension—a complex conundrum with many phenotypes? Pediatr Res. 2023 Aug 01;94(2):416–417. doi: 10.1038/s41390-023-02578-2
   PubMed Web of Science ®Google Scholar
• Kitaoka H, Konishi T, Shitara Y, et al. Effects of Milrinone on neonates after patent ductus arteriosus ligation: a retrospective nationwide database study. Neonatology. 2023;120(6):751–759. doi: 10.1159/000533958
   PubMed Web of Science ®Google Scholar
• Evans P, O’Reilly D, Flyer JN, et al. Indomethacin for symptomatic patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev. 2021 Jan 15;1(1):CD013133. doi: 10.1002/14651858.CD013133.pub2
   PubMedGoogle Scholar
• Abdi HH, Backes CH, Ball MK, et al. Prophylactic indomethacin in extremely preterm infants: association with death or BPD and observed early serum creatinine levels. J Perinatol. 2021 Apr;41(4):749–755. doi: 10.1038/s41372-021-00995-x
   PubMed Web of Science ®Google Scholar
• Hundscheid T, Onland W, Kooi EMW, et al. Expectant management or early ibuprofen for patent ductus arteriosus. N Engl J Med. 2023 Mar 16;388(11):980–990. doi: 10.1056/NEJMoa2207418
   PubMed Web of Science ®Google Scholar
• Gupta S, Subhedar NV, Bell JL, et al. Trial of selective early treatment of patent ductus arteriosus with ibuprofen. N Engl J Med. 2024 Jan 25;390(4):314–325. doi: 10.1056/NEJMoa2305582
   PubMed Web of Science ®Google Scholar
• Jasani B, Mitra S, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database Syst Rev. 2022 Dec 15;12:CD010061. doi: 10.1002/14651858.CD010061.pub5
   PubMedGoogle Scholar
• Mitra S, Scrivens A, von Kursell AM, et al. Early treatment versus expectant management of hemodynamically significant patent ductus arteriosus for preterm infants. Cochrane Database Syst Rev. 2020 Dec 10;12(12):CD013278.
   PubMedGoogle Scholar
• De Paepe ME, Mao Q, Powell J, et al. Growth of pulmonary microvasculature in ventilated preterm infants. Am J Respir Crit Care Med. 2006 Jan 15;173(2):204–211. doi: 10.1164/rccm.200506-927OC
   PubMed Web of Science ®Google Scholar
• Galambos C, Sims-Lucas S, Abman SH. Histologic evidence of intrapulmonary anastomoses by three-dimensional reconstruction in severe bronchopulmonary dysplasia. Ann Am Thorac Soc. 2013 Oct;10(5):474–481. doi: 10.1513/AnnalsATS.201305-124OC
   PubMedGoogle Scholar
• Al-Ghanem G, Shah P, Thomas S, et al. Bronchopulmonary dysplasia and pulmonary hypertension: a meta-analysis. J Perinatol. 2017 Apr;37(4):414–419. doi: 10.1038/jp.2016.250
   PubMed Web of Science ®Google Scholar
• Sheth S, Goto L, Bhandari V, et al. Factors associated with development of early and late pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. J Perinatol. 2020 Jan;40(1):138–148. doi: 10.1038/s41372-019-0549-9
   PubMed Web of Science ®Google Scholar
• Khemani E, McElhinney DB, Rhein L, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics. 2007 Dec;120(6):1260–1269. doi: 10.1542/peds.2007-0971
   PubMed Web of Science ®Google Scholar
• Del Cerro Mj, Sabate Rotes A, Carton A, et al. Pulmonary hypertension in bronchopulmonary dysplasia: clinical findings, cardiovascular anomalies and outcomes. Pediatr Pulmonol. 2014 Jan;49(1):49–59. doi: 10.1002/ppul.22797
   PubMed Web of Science ®Google Scholar
• Arattu Thodika FMS, Nanjundappa M, Dassios T, et al. Pulmonary hypertension in infants with bronchopulmonary dysplasia: risk factors, mortality and duration of hospitalisation. J Perinat Med. 2022 Mar 28;50(3):327–333. doi: 10.1515/jpm-2021-0366
   PubMed Web of Science ®Google Scholar
• Häfner F, Johansson C, Schwarzkopf L, et al. Current diagnosis and treatment practice for pulmonary hypertension in bronchopulmonary dysplasia-A survey study in Germany (PUsH BPD). Pulm Circ. 2023 Oct;13(4):e12320. doi: 10.1002/pul2.12320
   PubMed Web of Science ®Google Scholar
• Abman SH, Chatfield BA, Hall SL, et al. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol. 1990 Dec;259(6 Pt 2):H1921–7. doi: 10.1152/ajpheart.1990.259.6.H1921
   PubMedGoogle Scholar
• Shaul PW, Yuhanna IS, German Z, et al. Pulmonary endothelial NO synthase gene expression is decreased in fetal lambs with pulmonary hypertension. Am J Physiol. 1997 May;272(5 Pt 1):L1005–12. doi: 10.1152/ajplung.1997.272.5.L1005
   PubMedGoogle Scholar
• North AJ, Lau KS, Brannon TS, et al. Oxygen upregulates nitric oxide synthase gene expression in ovine fetal pulmonary artery endothelial cells. Am J Physiol. 1996 Apr;270(4 Pt 1):L643–9. doi: 10.1152/ajplung.1996.270.4.L643
   PubMedGoogle Scholar
• Abman SH, Wolfe RR, Accurso FJ, et al. Pulmonary vascular response to oxygen in infants with severe bronchopulmonary dysplasia. Pediatrics. 1985 Jan;75(1):80–84. doi: 10.1542/peds.75.1.80
   PubMed Web of Science ®Google Scholar
• Van Obbergh LJ, Charbonneau M, Blaise G. Combination of inhaled nitric oxide with i.V. nitroglycerin or with a prostacyclin analogue in the treatment of experimental pulmonary hypertension. Br J Anaesth. 1996 Aug;77(2):227–231. doi: 10.1093/bja/77.2.227
   PubMed Web of Science ®Google Scholar
• Perez KM, Laughon M. Sildenafil in term and premature infants: a systematic review. Clin Ther. 2015 Nov 1;37(11):2598–2607 e1. doi: 10.1016/j.clinthera.2015.07.019
   PubMed Web of Science ®Google Scholar
• Konig K, Barfield CP, Guy KJ, et al. The effect of sildenafil on evolving bronchopulmonary dysplasia in extremely preterm infants: a randomised controlled pilot study. J Matern Fetal Neonatal Med. 2014 Mar;27(5):439–444. doi: 10.3109/14767058.2013.818650
   PubMed Web of Science ®Google Scholar
• Mourani PM, Sontag MK, Ivy DD, et al. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr. 2009 Mar;154(3):379–84, 384 e1–2. doi: 10.1016/j.jpeds.2008.09.021
   Web of Science ®Google Scholar
• Kadmon G, Schiller O, Dagan T, et al. Pulmonary hypertension specific treatment in infants with bronchopulmonary dysplasia. Pediatr Pulmonol. 2017 Jan;52(1):77–83. doi: 10.1002/ppul.23508
   PubMed Web of Science ®Google Scholar
• Jeremiasen I, Tran-Lundmark K, Dolk M, et al. Outpatient prescription of pulmonary vasodilator therapy to preterm children with bronchopulmonary dysplasia. Acta Paediatr. 2023 Mar;112(3):409–416. doi: 10.1111/apa.16615
   PubMed Web of Science ®Google Scholar
• Steinhorn RH, Fineman J, Kusic-Pajic A, et al. Bosentan as adjunctive therapy for persistent pulmonary hypertension of the newborn: results of the randomized multicenter placebo-controlled exploratory trial. J Pediatr. 2016 Oct;177:90–96 e3. doi: 10.1016/j.jpeds.2016.06.078
   PubMed Web of Science ®Google Scholar
• Gao N, Lv Y, Cui Y, et al. Bosentan in the treatment of persistent pulmonary hypertension in newborns: a systematic review and meta-analysis. Cardiol Young. 2024 Feb;8:1–8. doi: 10.1017/S1047951123004456
   Google Scholar
• Sahni M, Bhandari V. Bronchopulmonary dysplasia-associated pulmonary hypertension. Pediatr Med. 2019;2:4–4. doi: 10.21037/pm.2019.02.01
   Google Scholar
• Olave N, Lal CV, Halloran B, et al. Iloprost attenuates hyperoxia-mediated impairment of lung development in newborn mice. Am J Physiol Lung Cellular Mol Physiol. 2018 Oct 1;315(4):L535–L544. doi: 10.1152/ajplung.00125.2017
   PubMed Web of Science ®Google Scholar
• Sehgal A, Krishnamurthy MB, Clark M, et al. ACE inhibition for severe bronchopulmonary dysplasia - an approach based on physiology. Physiol Rep. 2018 Sep;6(17):e13821. doi: 10.14814/phy2.13821
   PubMedGoogle Scholar
• Xia Y, Lang T, Niu Y, et al. Phase I trial of human umbilical cord-derived mesenchymal stem cells for treatment of severe bronchopulmonary dysplasia. Genes Dis. 2023 Mar;10(2):521–530. doi: 10.1016/j.gendis.2022.02.001
   PubMed Web of Science ®Google Scholar
• Giva S, Abdelrahim A, Ojinna BT, et al. Safety and efficacy of mesenchymal stem cells for the treatment of evolving and established bronchopulmonary dysplasia: a systematic literature review. Cureus. 2022 Dec;14(12):e32598. doi: 10.7759/cureus.32598
   PubMed Web of Science ®Google Scholar
• Ahn SY, Chang YS, Lee MH, et al. Stem cells for bronchopulmonary dysplasia in preterm infants: a randomized controlled phase II trial. Stem Cells Transl Med. 2021 Aug;10(8):1129–1137. doi: 10.1002/sctm.20-0330
   PubMed Web of Science ®Google Scholar
• Ahn SY, Chang YS, Lee MH, et al. Five-year follow-up of phase II trial of stromal cells for bronchopulmonary dysplasia. Thorax. 2023 Nov;78(11):1105–1110. doi: 10.1136/thorax-2022-219622
   PubMed Web of Science ®Google Scholar